Close Menu

NEW YORK – Following a $6M Series A funding round earlier this month, Israeli personalized medicine company Curesponse will expand into the UK later this year by establishing a laboratory in London. 

The Rehovot-based firm plans to launch clinical trials for its cResponse technology, which uses ex vivo organ culture (EVOC) to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs prior to treatment.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.